ERBB2 and cancer: First Phase 3 success for FGFR2b-targeted therapy in this setting.Bemarituzumab + chemo significantly improves OS in FGFR2b+, HER2– G/GEJ cancer.Ocular side effects are manageable.Full efficacy data awaited.